IDH2 and astrocytoma (excluding glioblastoma): Interestingly, these tumors were epigenetically distinct from IDH-mutant astrocytomas, with reduced global methylation levels, and were distinguishable with methylation profiling from secondary MMR-deficient tumors, which tended to match better with their MMR-retained IDH-mutant astrocytoma counterparts [59, 200].